These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2994982)

  • 21. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs.
    Fernandez JH; Neshich G; Camargo AC
    Genet Mol Res; 2004 Dec; 3(4):554-63. PubMed ID: 15688321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity.
    Taddei S; Bortolotto L
    Am J Cardiovasc Drugs; 2016 Oct; 16(5):309-21. PubMed ID: 27260014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.
    Greco AJ; Master RG; Fokin A; Baber SR; Kadowitz PJ
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1163-75. PubMed ID: 17218981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin.
    Montenegro MF; Pessa LR; Tanus-Santos JE
    Eur J Pharmacol; 2009 Apr; 607(1-3):173-7. PubMed ID: 19233159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of pathophysiologic state on the metabolism of vasoactive peptides by mammalian lung.
    Stalcup SA; Leuenberger P; Greenbaum LM; Mellins RB; Turino GM
    Bull Eur Physiopathol Respir; 1979; 15(5):1031-44. PubMed ID: 228783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice.
    Campbell DJ; Alexiou T; Xiao HD; Fuchs S; McKinley MJ; Corvol P; Bernstein KE
    Hypertension; 2004 Apr; 43(4):854-9. PubMed ID: 14769811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration by kallikrein and bradykinin of the conversion of angiotensin I to angiotensin II in the isolated perfused rat lung.
    Ercan ZS; Bor NM; Torunoğlu M; Türker RK
    Arzneimittelforschung; 1982; 32(1):30-1. PubMed ID: 6174131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prothrombotic effects of angiotensin.
    Brown NJ; Vaughan DE
    Adv Intern Med; 2000; 45():419-29. PubMed ID: 10635057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In memory of Professor John H. Laragh.
    Volpe M
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):197. PubMed ID: 25943779
    [No Abstract]   [Full Text] [Related]  

  • 31. Proline rich-oligopeptides: diverse mechanisms for antihypertensive action.
    Morais KL; Ianzer D; Miranda JR; Melo RL; Guerreiro JR; Santos RA; Ulrich H; Lameu C
    Peptides; 2013 Oct; 48():124-33. PubMed ID: 23933300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
    Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
    Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and characterization of a bradykinin potentiating peptide (BPP-S) isolated from Scaptocosa raptoria venom.
    Ferreira LA; Alves WE; Lucas MS; Habermehl GG
    Toxicon; 1996 May; 34(5):599-603. PubMed ID: 8783454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the angiotensin I antagonist, SQ 20881, for lateralizing renal venous renin activity.
    Rosenthal T; Adar R; Stern N; Kisin E; Jacob ET; Rubinstein Z
    Isr J Med Sci; 1978 Mar; 14(3):388-91. PubMed ID: 640825
    [No Abstract]   [Full Text] [Related]  

  • 35. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG; Christie N
    Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme).
    Kalinina EV; Posdnev VF; Komissarova NV; Gomazkov OA
    Biochemistry (Mosc); 1997 Mar; 62(3):247-50. PubMed ID: 9275297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
    Patchett AA
    J Med Chem; 2002 Dec; 45(26):5609-16. PubMed ID: 12477342
    [No Abstract]   [Full Text] [Related]  

  • 38. [Antihypertensive therapy using a combination of angiotensin 1 receptor inhibitors with angiotensin-converting enzyme inhibitors].
    Meyer GJ
    Dtsch Med Wochenschr; 1998 May; 123(21):681. PubMed ID: 9638097
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.
    Sica DA; Gehr TW; Fernandez A
    Drug Saf; 2000 May; 22(5):350-60. PubMed ID: 10830252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.
    Chen Z; Tan F; Erdös EG; Deddish PA
    Hypertension; 2005 Dec; 46(6):1368-73. PubMed ID: 16246972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.